![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The collaboration combines SIRION’s adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy and expertise in viral vector development and production with CRG’s deep knowledge of genetic regulatory mechanisms.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Recipient: Sirion Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 16, 2022